Filing Flows › Nurix Therapeutics (NRIX) › Q1 FY26
Nurix Therapeutics (NRIX) Q1 FY26 earnings results (first quarter fiscal 2026)
10-Q filed Apr 8, 2026
Nurix Therapeutics (NRIX) reported revenue of $6.3M for the first quarter fiscal 2026 (Q1 FY26), -66% from a year earlier and -54% from the quarter before.
Nurix Therapeutics, Q1 FY26: revenue $6.3M (-66% year over year), net loss $87.2M, operating cash flow −$71.9M. The chart follows the revenue to costs, profit and cash.
| Q1 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $6.3M | -54% | -66% |
| Operating profit | −$92.5M | — | — |
| Net earnings | −$87.2M | — | — |
| Operating cash flow | −$71.9M | — | — |
What changed
Revenue was $6.3M in Q1 FY26, down 66% year over year and down 54% from the previous quarter.
Operating costs exceeded revenue by $92.5M, an operating margin of -1479.4%. Total costs grew 21% against a revenue fall of 66%. The fastest-growing cost line was General & admin (+25%). The quarter ended with a net loss of $87.2M, wider than the previous quarter's $78.2M loss.
Operating cash flow was −$71.9M. Non-cash charges added back $2.2M of depreciation and amortization and $9.4M of share-based compensation. Working capital and other items added $3.7M. Capital expenditures of $1.0M exceeded it, leaving free cash flow of −$73.0M.
Questions
What was Nurix Therapeutics' revenue in the first quarter fiscal 2026?
Nurix Therapeutics (NRIX) reported revenue of $6.3M for the first quarter fiscal 2026 (Q1 FY26), -66% from a year earlier and -54% from the quarter before.
Source: Nurix Therapeutics 10-Q on SEC EDGAR.